Abstract:Background: Remuscularization of the mammalian heart can be achieved after cell transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). However, several hurdles remain before implementation into clinical practice. Poor survival of the implanted cells is related to insufficient vascularization, and the potential for fatal arrhythmogenesis is associated with the fetal cell-like nature of immature CMs. Methods: We generated 3 lines of hiPSC-derived endothelial cells (ECs) and hiPSC-CMs from 3 independent donors and tested hiPSC-CM sarcomeric length, gap junction protein, and calcium-handling ability in coculture with ECs. Next, we examined the therapeutic effect of the cotransplantation of hiPSC-ECs and hiPSC-CMs in nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice undergoing myocardial infarction (n≥4). Cardiac function was assessed by echocardiography, whereas arrhythmic events were recorded using 3-lead ECGs. We further used healthy non-human primates (n=4) with cell injection to study the cell engraftment, maturation, and integration of transplanted hiPSC-CMs, alone or along with hiPSC-ECs, by histological analysis. Last, we tested the cell therapy in ischemic reperfusion injury in non-human primates (n=4, 3, and 4 for EC+CM, CM, and control, respectively). Cardiac function was evaluated by echocardiography and cardiac MRI, whereas arrhythmic events were monitored by telemetric ECG recorders. Cell engraftment, angiogenesis, and host-graft integration of human grafts were also investigated. Results: We demonstrated that human iPSC-ECs promote the maturity and function of hiPSC-CMs in vitro and in vivo. When cocultured with ECs, CMs showed more mature phenotypes in cellular structure and function. In the mouse model, cotransplantation augmented the EC-accompanied vascularization in the grafts, promoted the maturity of CMs at the infarct area, and improved cardiac function after myocardial infarction. Furthermore, in non-human primates, transplantation of ECs and CMs significantly enhanced graft size and vasculature and improved cardiac function after ischemic reperfusion. Conclusions: These results demonstrate the synergistic effect of combining iPSC-derived ECs and CMs for therapy in the postmyocardial infarction heart, enabling a promising strategy toward clinical translation.

Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique

Incorporating protein transduction domains (PTD) within intracellular proteins associated with the ‘stemness’ phenotype. Novel use of such recombinant ‘fusion’ proteins to overcome current limitations of applying autologous adult stem cells in regenerative medicine?

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Cell Transplantation and Tissue Regeneration Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique

Abstract 9374: Zinc Finger Nuclease Technology for Human Pluripotent Stem Cell Genomic Modification and in Vivo Tracking

In Vivo Reprogramming of Mouse Fibroblasts into Cardiac Progenitor Cells for Myocardial Infarction Treatment

Early Stem Cell Engraftment Predicts Late Cardiac Functional Recovery: Preclinical Insights from Molecular Imaging.

Abstract 210: Reprogramming Mouse Fibroblasts Into Cardiac Progenitor Cells Using Crispr Technique Targeting Endogenic Genes

Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts

Lineage Reprogramming Of Fibroblasts Into Expandable Cardiac Progenitor Cells By Defined Small Molecules

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Abstract 16620: Enhancing Transplanted Cardiac Progenitor Cells Homing and Survival in Ischemic Heart by CRISPR-dcas9/sgRNA-based Endogenous CXCR4 Promoter Activation

Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates

Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression

Direct in Vivo Reprogramming with Non-Viral Sequential Targeting Nanoparticles Promotes Cardiac Regeneration.

CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy

Transplantation of Multipotent Isl1+ Cardiac Progenitor Cells Preserves Infarcted Heart Function in Mice.

Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus

Pharmacologically inducing regenerative cardiac cells by small molecule drugs

Dual Gene-Loaded Near-Infrared AIEgen Nanoplatforms with Promoted Proliferation, Relieved Immunosuppression, and Tracking Capabilities for Cardiomyocyte Transplantation

Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails